Discovery Holdings

C4X Discovery Holdings is a UK-based drug discovery company that leverages proprietary technologies to design best-in-class small molecule candidates. The company's core platforms, Conformetrix and Taxonomy3, allow for the precise determination of molecular 3D structures in solution and the identification of novel genetic targets, respectively. C4X focuses primarily on immuno-inflammation and has successfully out-licensed several high-value programs to major pharmaceutical partners, including AstraZeneca and Sanofi. Its business model emphasizes early-stage discovery and strategic partnerships to advance its pipeline toward clinical development.